| Withdrawn | Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma NCT05341947 | Jeremy Rudnick, M.D | Phase 1 |
| Not Yet Recruiting | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma NCT07416188 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 / Phase 2 |
| Not Yet Recruiting | BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma NCT04903795 | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Phase 1 |
| Not Yet Recruiting | Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma NCT07346144 | Trogenix ltd | Phase 1 / Phase 2 |
| Recruiting | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma NCT07480941 | Beijing Biotech | Phase 1 |
| Recruiting | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Pa NCT07297212 | BioNTech SE | Phase 2 |
| Recruiting | Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM NCT07209241 | University of Pennsylvania | Phase 1 |
| Recruiting | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma NCT06910306 | Alpha Tau Medical LTD. | N/A |
| Recruiting | B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Gliobl NCT07193628 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Trea NCT07076472 | Mayo Clinic | EARLY_Phase 1 |
| Not Yet Recruiting | Phase 2 Clinical Trial of KH617 NCT07138001 | Sichuan Honghe Biotechnology Co., Ltd. | Phase 2 |
| Recruiting | CUE-102 in Recurrent Glioblastoma NCT06917885 | David Reardon, MD | Phase 1 |
| Recruiting | Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent o NCT06815029 | City of Hope Medical Center | Phase 1 |
| Recruiting | Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma NCT06613841 | Abramson Cancer Center at Penn Medicine | EARLY_Phase 1 |
| Withdrawn | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma NCT06501911 | University of Nebraska | Phase 1 |
| Not Yet Recruiting | Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature NCT06894225 | National Neuroscience Institute | Phase 2 |
| Recruiting | A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma NCT06552260 | Ugonma Chukwueke | EARLY_Phase 1 |
| Recruiting | OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pem NCT06558214 | University of Florida | Phase 2 |
| Active Not Recruiting | RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) NCT06389591 | University of Florida | Phase 1 |
| Suspended | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatme NCT06325683 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | A Study of BL-B01D1 in Patients With Recurrent Glioblastoma NCT06598787 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma NCT06160206 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma NCT06344130 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Open NCT05879120 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells NCT06186401 | Hideho Okada, MD, PhD | Phase 1 |
| Recruiting | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The NCT06069726 | Duke University | Phase 2 |
| Recruiting | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Niv NCT06097975 | Universitair Ziekenhuis Brussel | Phase 1 |
| Recruiting | Sonodynamic Therapy in Patients With Recurrent GBM NCT06039709 | Shayan Moosa, MD | Phase 1 |
| Active Not Recruiting | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent NCT05902169 | CarThera | Phase 3 |
| Completed | Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin NCT05977738 | C.Dirven | EARLY_Phase 1 |
| Recruiting | The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Gliobl NCT06220552 | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Unknown | A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma NCT05802693 | Beijing Tsinghua Chang Gung Hospital | EARLY_Phase 1 |
| Withdrawn | Reirradiation and Niraparib in Patients With Recurrent Glioblastoma NCT05666349 | University College, London | Phase 1 |
| Not Yet Recruiting | Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblast NCT05540275 | Henan Provincial People's Hospital | Phase 2 |
| Recruiting | Tris-CAR-T Cell Therapy for Recurrent Glioblastoma NCT05577091 | Beijing Tiantan Hospital | Phase 1 |
| Recruiting | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer NCT06058988 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Gliobla NCT05798507 | Emory University | EARLY_Phase 1 |
| Recruiting | Pilot Trial for Treatment of Recurrent Glioblastoma NCT05432518 | AHS Cancer Control Alberta | EARLY_Phase 1 |
| Unknown | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma NCT04077866 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 / Phase 2 |
| Unknown | Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients NCT05638451 | Zhujiang Hospital | Phase 2 |
| Recruiting | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma NCT05557292 | Nicholas Butowski | Phase 1 |
| Withdrawn | Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma NCT05410301 | Varun Monga, MD | N/A |
| Recruiting | CARv3-TEAM-E T Cells in Glioblastoma NCT05660369 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Recruiting | Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma NCT05043701 | Oslo University Hospital | EARLY_Phase 1 |
| Unknown | Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab NCT05737368 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) NCT06283927 | Jasper Gerritsen | — |
| Recruiting | The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma NCT06273176 | Erasmus Medical Center | — |
| Terminated | Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-gra NCT05737212 | Dawonmedax Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma NCT04385173 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Unknown | LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas NCT05663125 | Beijing Tiantan Hospital | Phase 1 / Phase 2 |
| Recruiting | Surgical Pembro +/- Olaparib w TMZ for rGBM NCT05463848 | L. Nicolas Gonzalez Castro, MD, PhD | Phase 2 |
| Terminated | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma NCT05324501 | Biodexa Pharmaceuticals | Phase 1 |
| Recruiting | Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma NCT05284643 | University of Miami | N/A |
| Recruiting | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma NCT05039281 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma NCT05236036 | Northwestern University | Phase 1 |
| Recruiting | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recur NCT05303467 | Boston Scientific Corporation | Phase 1 |
| Terminated | PARP Inhibition for Gliomas (PI-4G or π4g) NCT05297864 | University of Oklahoma | Phase 2 |
| Recruiting | Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblas NCT06090903 | Jonsson Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Natural Progesterone for the Treatment of Recurrent Glioblastoma NCT05091866 | Emory University | EARLY_Phase 1 |
| Active Not Recruiting | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recur NCT04729959 | National Cancer Institute (NCI) | Phase 2 |
| Completed | ASP8374 + Cemiplimab in Recurrent Glioma NCT04826393 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients NCT05191784 | Genexine, Inc. | Phase 2 |
| Active Not Recruiting | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rG NCT05118776 | Ascletis Pharmaceuticals Co., Ltd. | Phase 3 |
| Recruiting | Sacituzumab Govitecan in Recurrent Glioblastoma NCT04559230 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Unknown | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma NCT05201326 | Ruijin Hospital | Phase 1 |
| Unknown | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CS NCT05131711 | Beijing Tiantan Hospital | Phase 1 / Phase 2 |
| Terminated | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab NCT04681677 | Xoft, Inc. | Phase 2 |
| Unknown | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma NCT04888611 | Huashan Hospital | Phase 2 |
| Withdrawn | Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma NCT05017610 | Emory University | EARLY_Phase 1 |
| Unknown | Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma NCT04717999 | UWELL Biopharma | N/A |
| Withdrawn | Role of Repeat Resection in Recurrent Glioblastoma NCT04838782 | University of Alberta | N/A |
| Unknown | Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients NCT05108012 | Royan Institute | Phase 1 |
| Terminated | Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM) NCT04952571 | Beijing Sanbo Brain Hospital | Phase 2 |
| Completed | Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM NCT04988750 | NaviFUS Corporation | N/A |
| Withdrawn | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma NCT04854044 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma NCT04590664 | Emory University | Phase 1 / Phase 2 |
| Unknown | Niraparib Combined With Radiotherapy in rGBM NCT04715620 | Tianjin Huanhu Hospital | Phase 2 |
| Completed | Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd NCT04740190 | The University of Hong Kong | Phase 2 |
| Unknown | TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine NCT04671459 | Prof. Franciszek Lukaszczyk Memorial Oncology Center | Phase 2 |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 | Nuvation Bio Inc. | Phase 1 |
| Completed | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monothera NCT04417088 | InSightec | Phase 1 / Phase 2 |
| Active Not Recruiting | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Gliobl NCT04528680 | Northwestern University | Phase 1 / Phase 2 |
| Completed | LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma NCT04479241 | Istari Oncology, Inc. | Phase 2 |
| Completed | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM NCT04440358 | InSightec | Phase 1 / Phase 2 |
| Recruiting | Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children NCT04323046 | Sabine Mueller, MD, PhD | Phase 1 |
| Unknown | Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery NCT04223999 | Anders Rosendal Korshøj | Phase 2 |
| Active Not Recruiting | Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma NCT04477200 | University of Michigan Rogel Cancer Center | Phase 1 |
| Terminated | VB-111 in Surgically Accessible Recurrent/Progressive GBM NCT04406272 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treati NCT04469075 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279 | Sapience Therapeutics | Phase 1 / Phase 2 |
| Completed | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Pati NCT04657315 | CHA University | Phase 1 / Phase 2 |
| Completed | Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence NCT04013672 | David Peereboom | Phase 2 |
| Completed | Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma NCT04205357 | Haukeland University Hospital | Phase 1 |
| Active Not Recruiting | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ R NCT04214392 | City of Hope Medical Center | Phase 1 |
| Completed | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations NCT03914742 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma NCT04201873 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Niraparib/TTFields in GBM NCT04221503 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM NCT04003649 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Re NCT03014804 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab NCT03856099 | PharmAbcine | Phase 2 |
| Active Not Recruiting | Fimepinostat in Treating Brain Tumors in Children and Young Adults NCT03893487 | Sabine Mueller, MD, PhD | EARLY_Phase 1 |
| Completed | Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma NCT04051606 | Case Comprehensive Cancer Center | Phase 2 |
| Unknown | Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib NCT04004975 | Shandong Cancer Hospital and Institute | Phase 1 / Phase 2 |
| Unknown | CD147-CART Cells in Patients With Recurrent Malignant Glioma. NCT04045847 | Xijing Hospital | EARLY_Phase 1 |
| Active Not Recruiting | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas NCT03749187 | University of California, San Francisco | Phase 1 |
| Recruiting | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma NCT03896568 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma NCT03722342 | PharmAbcine | Phase 1 |
| Completed | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma NCT03782415 | MediciNova | Phase 1 / Phase 2 |
| Completed | Feasibility of Individualized Therapy for Recurrent Glioblastoma NCT03681028 | Jennifer Clarke | Phase 1 |
| Terminated | Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Gliobl NCT03430791 | Baptist Health South Florida | Phase 2 |
| Completed | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Gliobl NCT03732352 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Unknown | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma NCT03750071 | Vaximm GmbH | Phase 1 / Phase 2 |
| Completed | Mathematical Model-Adapted Radiation In Glioblastoma NCT03557372 | Dana-Farber Cancer Institute | N/A |
| Completed | Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms NCT04044937 | Thomas Hope | Phase 2 |
| Withdrawn | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma NCT03275558 | Center Trials & Treatment | Phase 1 |
| Completed | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma NCT01904123 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer NCT03107780 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM NCT03283631 | Gary Archer Ph.D. | Phase 1 |
| Completed | Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma NCT03632135 | Cordgenics, LLC | Phase 3 |
| Terminated | Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjec NCT03573986 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Active Not Recruiting | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma NCT02974621 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplasti NCT03022578 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma NCT03216499 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma NCT03115333 | ECOG-ACRIN Cancer Research Group | N/A |
| Completed | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery NCT03020017 | Northwestern University | EARLY_Phase 1 |
| Completed | Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma NCT03034135 | Cantex Pharmaceuticals | Phase 2 |
| Completed | BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab NCT03020602 | Seema Nagpal | Phase 1 |
| Completed | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma NCT02101905 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma NCT02794883 | Northwestern University | Phase 2 |
| Completed | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma NCT02661282 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma NCT02844439 | Kadmon Corporation, LLC | Phase 2 |
| Active Not Recruiting | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients Wit NCT02192359 | City of Hope Medical Center | Phase 1 |
| Completed | Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma NCT03033524 | PharmAbcine | Phase 2 |
| Active Not Recruiting | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma NCT02208362 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Recurrent Glioblastoma NCT02337686 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma NCT02340156 | SynerGene Therapeutics, Inc. | Phase 2 |
| Terminated | Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Gliob NCT01925573 | University of Maryland, Baltimore | N/A |
| Completed | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without NCT02017717 | Bristol-Myers Squibb | Phase 3 |
| Withdrawn | A Phase III Study of Re-Irradiation in Recurrent Glioblastoma NCT01830101 | AHS Cancer Control Alberta | Phase 3 |
| Completed | FMISO PET Study of Glioblastoma NCT02076152 | Massachusetts General Hospital | N/A |
| Completed | Vaccine Therapy in Treating Patients With Recurrent Glioblastoma NCT03360708 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Bevacizumab w / Temozolomide PET & Vascular MRI For GBM NCT01987830 | Massachusetts General Hospital | N/A |
| Completed | Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Gliobl NCT01849146 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Mul NCT01814813 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glio NCT01754350 | Johann Wolfgang Goethe University Hospital | N/A |
| Completed | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors NCT01609790 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma NCT01349036 | Daiichi Sankyo | Phase 2 |
| Completed | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma NCT01498328 | Celldex Therapeutics | Phase 2 |
| Completed | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurren NCT01266031 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | BIBF 1120 in Recurrent Glioblastoma Multiforme NCT01251484 | Ulrik Lassen | Phase 2 |
| Withdrawn | A Panobinostat Presurgery NCT01115036 | Duke University | Phase 2 |
| Completed | Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma NCT00777153 | AstraZeneca | Phase 3 |
| Completed | Ketogenic Diet for Recurrent Glioblastoma NCT00575146 | University Hospital Tuebingen | Phase 1 |
| Completed | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas NCT00586508 | Eli Lilly and Company | Phase 2 |
| Completed | Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour NCT00503204 | AstraZeneca | Phase 1 |
| Completed | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme NCT00390299 | Mayo Clinic | Phase 1 |
| Completed | Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research NCT00250887 | University of Zurich | Phase 2 |
| Active Not Recruiting | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Res NCT00102648 | M.D. Anderson Cancer Center | Phase 1 |
| No Longer Available | Individual Patient Compassionate Use of GX-I7 NCT04289155 | Genexine, Inc. | — |
| No Longer Available | TVI-Brain-1 in Expanded Access Patient NCT05936216 | TVAX Biomedical | — |